Shandong Boan Biotechnology Co., Ltd
Quick facts
Phase 3 pipeline
- LY01008 · Oncology
LY01008 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. - LY01015
LY01015 is a small molecule inhibitor that targets a specific molecular pathway involved in disease pathogenesis.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Shandong Boan Biotechnology Co., Ltd portfolio CI brief
- Shandong Boan Biotechnology Co., Ltd pipeline updates RSS
Frequently asked questions about Shandong Boan Biotechnology Co., Ltd
What is Shandong Boan Biotechnology Co., Ltd's pipeline?
Shandong Boan Biotechnology Co., Ltd has 2 drugs in Phase 3, 0 in Phase 2, 4 in Phase 1. Late-stage candidates include LY01008, LY01015.
Related
- Sector hub: All tracked pharma companies